REGENERON PHARMACEUTICALS INC

REGN | NASDAQ/NGS (GLOBAL SELECT MARKET)

Business Summary

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company helps in accelerating and improving the traditional drug development process through its VelociSuite technologies, such as VelocImmune, which uses genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; Kevzara (sarilumab) Injection, and others.

Country of Incorporation

United States of America

Incorporation Date

1988-01-11

Business Sector

Pharmaceuticals & Medical Research

Company Address

777 Old Saw Mill River Road

Get access to the below data and more business development tools by signing up for the MENA Company Data product.

- Ownership details

- Corporate structure

- Business classification

- Officers & Directors contact details

- Full company contact details

Find out more

Multiply your reach by contributing your content to LSEG

LSEG contributed content reaches tens of thousands of buy and sell side professionals around the world through an integrated suite of market intelligence and transaction platforms.

Find out more